Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

The drug combination was safe and showed promise in treating advanced tumors.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Indinavir therapy can cause reversible skin, hair, and nail darkening.

Six African American women experienced hair loss after switching to a new HIV medication.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Upadacitinib may cause hair loss.

An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Divalproex sodium can cause pleural effusion, which stops when the drug is discontinued.